Novel DNA sequence variations of cytochrome P450 genes in the Han Chinese population

Pharmacogenomics

Volumn 10, Issue 3, 2009, Pages 359-374

  Wang, Hui Hung ^a   Liao, Yie Wen ^a   Chiang, Hung Lun ^a   Wu, Jer Yuarn ^a,b   Chen, Yuan Tsong ^a,c  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cytochrome P450; Direct sequence; Han Chinese; Novel variants; Taiwan

Indexed keywords

ADENINE; ASPARTIC ACID; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2A13; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 2J2; CYTOCHROME P450 3A5; CYTOSINE; GLUTAMIC ACID; GLYCINE; GUANINE; ISOLEUCINE; LEUCINE; PROLINE; THYMINE; TRYPTOPHAN; UNCLASSIFIED DRUG; VALINE;

ARTICLE; CHINESE; DNA SEQUENCE; DRUG METABOLISM; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC DATABASE; GENETIC VARIABILITY; HUMAN; INTRON; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; POPULATION GENETICS; PROTEIN FUNCTION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; ASIAN; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; GEOGRAPHY; REFERENCE VALUE; TAIWAN; TRANSPOSON;

ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; DATABASES, GENETIC; DNA TRANSPOSABLE ELEMENTS; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; GEOGRAPHY; HUMANS; INTRONS; POLYMORPHISM, GENETIC; REFERENCE VALUES; TAIWAN;

EID: 65649121831     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.10.3.359     Document Type: Article

References (34)

1. Seliskar M, Rozman D: Mammalian cytochromes P450 - importance of tissue specificity. Biochim. Biophys. Acta 1770, 458-466 (2007).
2. Lewis DF: 57 varieties: the human cytochromes P450. Pharmacogenomics 5, 305-318 (2004).
3. Guengerich FP: Cytochrome p450 and chemical toxicology. Chem. Res. Toxicol. 21, 70-83 (2008).
4. Wienkers LC, Heath TG: Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discov. 4, 825-833 (2005).
5. Thummel KE, Wilkinson GR: In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. 38, 389-430 (1998).
6. Gardiner SJ, Begg EJ: Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol. Rev. 58, 521-590 (2006).
7. Meyer UA: Pharmacogenetics and adverse drug reactions. Lancet 356, 1667-1671 (2000).
8. Wen MS, Lee M, Chen JJ et al.: Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin. Pharmacol. Ther. 84, 83-89 (2008).
9. Solus JF, Arietta BJ, Harris JR et al.: Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 5, 895-931 (2004).
10. Bradford LD: CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3, 229-243 (2002).
11. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S: CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet. Genomics 17, 93-101 (2007).
12. Chen L, Qin S, Xie J et al.: Genetic polymofphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics 9, 691-702 (2008).
13. Pitarque M, von Richter O, Oke B, Berkkan H, Oscarson M, Ingelman-Sundberg M: Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem. Biophys. Res. Commun. 284, 455-460 (2001).
14. Oscarson M, McLellan RA, Asp V et al.: Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Hum. Mutat. 20, 275-283 (2002).
15. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F: Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem. Biophys. Res. Commun. 254, 628-631 (1999).
16. Yang JQ, Morin S, Vefstuyft C et al.: Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam. Clin. Pharmacol. 17, 373-376 (2003).
17. Yuan HY, Chen JJ, Lee MT et al.: A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet. 14, 1745-1751 (2005).
18. Liou YH, Lin CT, Wu YJ, Wu LS: The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population. J. Hum. Genet. 51, 857-863 (2006).
19. Liao LH, Zhang H, Lai MP et al.: The association of CYP2C9 gene polymorphisms with colorectal carcinoma in Han Chinese. Clin. Chim. Acta 380, 191-196 (2007).
20. Pan WH, Fann CS, Wu JY et al.: Han Chinese cell and genome bank in Taiwan: purpose, design and ethical considerations. Hum. Hered. 61, 27-30 (2006).
21. Lundqvist E, Johansson I. Ingelman-Sundberg M: Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 226, 327-338 (1999).
22. Fukuda T, Maune H, Ikenaga Y, Naohara M, Fukuda K, Azuma J: Novel structure of the CYP2D6 gene that confuses genotyping for the CYP2D6*5 allele. Drug Metab. Pharmacokinet. 20, 345-350 (2005).
23. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 291, 1304-1351 (2001).
24. Wang SL, Lai MD, Huang JD: G169R mutation diminishes the metabolic activity of CYP2136 in Chinese. Drug Metab. Dispos. 27, 385-388 (1999).
25. Ji L, Pan S, Marti-Jaun J, Hanseler E, Rentsch K, Hersberger M: Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele, frequencies and a novel *14B allele in mainland Chinese. Clin. Chem. 48, 983-988 (2002).
26. Broly F, Marez D, Lo Guidice JM et al.: A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency. Hum. Genet. 96, 601-603 (1995).
27. Garcia-Barcelo M, Chow Ly, Chiu HF et al. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin. Chem. 46, 18-23 (2000).
28. Lee EJ, Jeyaseelan K: Frequency of human CYP2D6 mutant alleles in a normal Chinese population. Br. J. Clin. Pharmarol. 37, 605-607 (1994).
29. Wang SL, Huang JD, Mai MD, Liu BH, Lai ML: Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin. Pharmacol. Ther. 53, 410-418 (1993).
30. Yoshida R, Nakajima M, Nishimura K, Tokudome S, Kwon JT, Yokoi T: Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin. Pharmacol. Ther. 74, 69-76 (2003).
31. Jinno H, Tanaka-Kagawa, T, Ohno A et al.: Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab. Dispos. 31, 398-403 (2003).
32. Guan S, Huang M, Li X, Chen X, Chan E, Zhou SF: Intra- and inter-ethnic differences in the allele frequencies of cytochrome P450 2116 gene in Chinese. Pharm. Res. 23, 1983-1990 (2006).
33. Xiao ZS, Goldstein JA, Xie HG et al.: Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J. Pharmacol. Exp. Ther. 281, 604-609 (1997).
34. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M: Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 46, 452-459 (1994).